Skin Inflammation Clinical Trial
Official title:
Influence of TrueBroc® Broccoli Seed Extract Supplementation on Skin Health
The primary objective of this study is to examine the influence of 4-weeks ingestion of TrueBroc®, (broccoli seed extract, BSE) with mustard seed powder (MSP) on improving skin health by evaluating skin physiological and biochemical parameters. This study will test the effect of BSE and MSP compared to placebo on skin health after 4 weeks supplementation. The study will employ a randomized, crossover design with subjects acting as their own controls.
The primary objective of this study is to examine the influence of 4-weeks ingestion of TrueBroc® with mustard seed powder on improving skin health by evaluating skin physiological and biochemical parameters. TrueBroc® Glucoraphanin-Rich Broccoli Seed Extract (TrueBroc®) is a hot water extract of Brassica oleracea var. Italica Plenck (Brassicaceae) seeds. TrueBroc® contains high levels of glucoraphanin, a glucosinolate prominently found in the cruciferous vegetables. This study will use supplements containing 770 mg Broccoli Seed Extract (BSE) with 290 mg mustard seed powder (MSP) and 200 mg vitamin C. Limited data indicate that this mixture enhances glucoraphanin bioavailability. The consumption of the phytochemical glucoraphanin confers a number of benefits including skin health. Hypothesis: That 4-weeks ingestion of TrueBroc® with MSP compared to placebo will improve skin health. Study Procedures This study will incorporate a randomized, double-blinded, placebo-controlled, crossover design with 4-week supplementation and a 2-week washout period. Skin measurements and tape stripping samples will be collected pre- and post-4-week supplementation periods. Skin tape stripping samples will be analyzed for oxinflammatory-related outcomes. Blood and 24-hour urine samples will also be collected pre- and post-4-week supplementation periods. These samples will be aliquoted and stored in a freezer for potential analysis of targeted outcomes pending additional funding. Visit #1: Screening and Consent. Subjects will come to the Human Performance Lab at assigned times. The COVID-19 screening participant form will be filled in by the participant to verify the absence of symptoms or exposure.This visit will begin with a review of the consent form, and the inclusion and exclusion criteria. Height, body weight, body composition (seca BIA), and blood pressure will be measured. Subjects will be given 24-hour collection kits with instructions to collect all urine in the provided jug during the day before visit #2. Visit #2: Return urine bottles. Provide blood sample. Skin health measurements. Start 4-weeks supplementation. Subjects will come to the Human Performance Lab at assigned times in an overnight fasted state (no intake of food or beverages except for water during at least the previous 9 hours). Subjects will drop off the urine bottles and provide an overnight fasted blood sample. Skin health measurements will involve having probes and tapes applied to the surface of the skin to assess various parameters of skin health. Photos of skin areas will be taken. These skin health measurements will take about 15 to 30 minutes. A 4-week supply of capsules will be provided in supplement trays or bottles, and an additional 24-hour urine collection kit will be given to each subject. Subjects will be contacted weekly by the Research Manager to ensure adherence to the supplementation regimen (2 capsules per day, 4 weeks). Visit #3: Repeat visit #2 test procedures. Subjects will come to the Human Performance Lab at assigned times in an overnight fasted state after 4 weeks of supplementation. Subjects will drop off the urine bottles and provide a blood sample. Body composition and blood pressure measurements will be repeated. Skin health measurements will be repeated. An additional 24-hour urine collection kit will be given to each subject. Subjects will be instructed to return to the lab after the 2-week washout period. Visits #4 and #5: Repeated procedures from visits #2 and #3. Subjects will crossover to the opposite trial supplement and repeat all study procedures. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04479514 -
Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy
|
Phase 2 | |
Completed |
NCT03065504 -
Turmeric and Turmeric-containing Tablets and Sebum Production
|
N/A | |
Recruiting |
NCT05535738 -
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
|
Phase 2/Phase 3 | |
Recruiting |
NCT05277324 -
The Effect of Wearing Facial Masks on Skin Parameters During the COVID-19 Pandemic
|
||
Completed |
NCT05300542 -
Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema
|
N/A | |
Completed |
NCT03192280 -
Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response
|
N/A | |
Withdrawn |
NCT03976206 -
Very Small Embryonic-like Stem Cells for Facial Skin Antiaging
|
Phase 1/Phase 2 | |
Completed |
NCT05102604 -
The Effect of Avocado vs. Usual Diet on Skin Aging
|
N/A | |
Withdrawn |
NCT03862872 -
Effects of Bend Beauty's Anti-Aging Formula on Inflammatory Markers
|
N/A | |
Completed |
NCT04471896 -
Joovvin' for Your Skin Health Study
|
N/A | |
Recruiting |
NCT03581747 -
Detection of Skin Epithelial Barrier in Patients With Allergic Skin Disorders
|
||
Recruiting |
NCT06387212 -
35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Inflammation of Skin
|
N/A | |
Completed |
NCT05517720 -
An Exploratory Investigation of a Novel Skincare Regimen
|
N/A | |
Completed |
NCT05461456 -
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
|
Phase 1 |